Browsing Investigación Aplicada by Author "Rizzo, Manglio."
Now showing items 1-4 of 4
-
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
Rizzo, Manglio.; Martin, Claudio.; Lupinacci, Lorena.; Et al. (Elsevier, 2020-09)Abstract Background: Nivolumab was the first anti-programmed cell death 1 drug approved in Argentina for non-small-cell lung cancer treatment in the second-line setting. Materials and methods: The present study was a ... -
Is there a place for optimizing thoracic radiotherapy in limited-stage small cell lung cancer after twenty years?
Rizzo, Manglio.; Barros, José.; Chiozza, Jorge.; Et al. (Baishideng Publishing Group, 2021-01)Abstract Thoracic radiotherapy (TRT) is one of the main treatments in limited-stage small cell lung cancer (LS-SCLC). Hyperfractionated TRT (45 Gy, 1.5 Gy twice daily) has been the standard of care (SOC) since Turrisi and ... -
Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting
Videla, Alejandro.; Silva, Carlos.; Rizzo, Manglio.; Et al. (Springer, 2021-06)Abstract Background: Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status (PS) are underrepresented in clinical trials. We ... -
Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era
Rizzo, Manglio.; Mandó, Pablo.; Rivero, Sergio.; Et al. (Elsevier, 2021-12)Abstract The clinical outcome of patients with human epidermal growth factor receptor 2 (HER2) amplified breast carcinoma (BC) has improved with the development of anti-HER2 targeted therapies. However, patients can ...